Download the 'Programme'.
Download the 'Symposium summary - Day 1'.
Download the 'Career Bootcamp programme'.
Track 1: From bench to bedside: targeting the pathophysiological responses of ischemia-reperfusion injuries
In addition to covering the diverse mechanisms important in I/R injury of different organs, the work presented highlighted a broad spectrum of scientific approaches to the problem of I/R injury. This was to help stimulate cross-pollination of ideas between different clinical and non-clinical disciplines.
The Society’s Equality and Diversity Statement was followed in preparation of this symposium.
The objective of this symposium was to bring together scientists and clinicians of all levels to discuss the diverse nature of IRI and potential therapeutic strategies to treat this disease area.
Track 2: Recent developments in research of melatonin and its potential therapeutics applications
A role for melatonin in modulation of sleep rhythms has been researched extensively. However, recent developments in research of melatonin assign roles for this compound that impinge on a broader range of physiological systems. This symposium focused on melatonin and its receptors and their influence on mood, behaviour, inflammation and metabolism, including their potential for pharmacotherapy in these fields.
The objective of the symposium was to draw attention to recent developments in research of melatonin and its receptors and to highlight its potential as a target for pharmacotherapy in some prominent and diverse disorders.
Track 3a: The long reach of the bowel: translating microbiome science into therapeutics for systemic human diseases
The overall objective was to present new findings regarding GPCR expression in a variety of cell types and tissues and the role of newly recognized non-traditional and orphan GPCRs in regulating organ function and as potential therapeutic targets.
At the end of the program the audience had translational insights and a balanced view of the promise and challenges of microbiome hypothesis generation and testing, especially with respect to its metabolic role. They also learned about the latest pharmacological tools and potential therapeutic approaches for drug discovery using bacteria.
Track 3b: Resolution of inflammation: Translation to therapeutics
This symposium provided an overview of the field of resolution pharmacology and the potential for revolutionizing the treatment of inflammatory diseases, with examples of the broad range of endogenous mediators involved in this process, and the evolving clinical evidence suggesting that this approach will be successful.
Track 4: Non-traditional/orphan GPCRS as novel therapeutic targets
Professor Milligan provided an overview on the status of non-traditional/ orphan GPCRs and the opportunities that may exist to target such receptors with novel drugs (including biologics). The other speakers highlighted their findings that addressed several clinically important areas in need of new therapeutics (e.g., pulmonary hypertension, antibiotic resistance, Alzheimer’s Disease).
Track 5: Organ-on-a-chip technology - the future of physiological profiling?
(Sponsored by the Physiological Society and NC3Rs)
Tools which improve disease modelling and saftey pharmacology, as well as mitigate the use for animal testing are critical to the success of drug discovery and development.
Success in this area will rely on interdisciplinary relationships between pharmacologists, physiologists, physicists, drug developers and clinicians. In this symposium we aimed to bring together leading scientists and opinion leaders in these areas, in the hope of fostering collaborations and discussion to aid in improving the drug discovery and development process. As we represent the Young Pharmacologists Advisory Group of the British Pharmacological Society we also hoped this would provide an educational experience to young scientists and students, and provide networking opportunities.